Eric B. Berens

Eric B. Berens

Auto-generated profile, based on publicly available information

Eric B. Berens

Department of Anatomy, University of California, San Francisco, San Francisco, California

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
22 January 2025 in bioRxiv
Verified
Preprint
Open access
PDF file
EBEric B. Berens
Eric B. Berens
SKSokchea Khou
Sokchea Khou
EHElaine Huang
Elaine Huang
AHAmber Hoffman
Amber Hoffman
BJBriana Johnson
Briana Johnson
LCLisa M. Coussens
Lisa M. Coussens
Dedifferentiation programs are commonly enacted during breast cancer progression to enhance tumor cell fitness. Increased cellular plasticity within the neoplastic compartment of tumors correlates with disease aggressiveness, often culminating in greater resistance to cytotoxic therapies or augmented metastatic potential. Here we report that subpopulations of dedifferentiated neoplastic breast epithelial cells express canonical leukocyte cell surface receptor proteins and have thus named this cellular program “immune mimicry.” We document neoplastic cells engaging in immune mimicry within public human breast tumor single-cell RNA-seq datasets, histopathological breast tumor specimens, breast cancer cell lines, as well as in murine transgenic and cell line-derived mammary cancer models. Immune-mimicked neoplastic cells harbor hallmarks of dedifferentiation and are enriched in treatment-resistant and high-grade breast tumors. We corroborated these observations in aggressive breast cancer cell lines where anti-proliferative cytotoxic chemotherapies drove epithelial cells toward immune mimicry. Moreover, in subsequent proof-of-concept studies, we demonstrate that expression of the CD69 leukocyte activation protein by neoplastic cells confers a proliferative advantage that facilitates early tumor growth and therefore conclude that neoplastic breast epithelial cells upregulating leukocyte surface receptors potentiate malignancy. Moving forward, neoplastic immune mimicry should be evaluated for prognostic utility in additional breast cancer cohorts to determine its potential for patient stratification. Future research should evaluate correlates with distal metastases, progression-free survival, overall survival, and therapeutic response/resistance. Statement of Significance: Neoplastic breast epithelial cells express surface receptors canonically attributed to leukocytes and are associated with therapy resistance and aggressive tumor behavior.

23 October 2025 in Cancer Research
Verified
Journal Article
Closed access
EBEric B. Berens
Eric B. Berens
SKSokchea Khou
Sokchea Khou
EHElaine T. Huang
Elaine T. Huang
AHAmber Hoffman
Amber Hoffman
BJBriana Johnson
Briana Johnson
LCLisa M. Coussens
Lisa M. Coussens
Dedifferentiation programs are commonly enacted during breast cancer progression to enhance tumor cell fitness. Increased cellular plasticity within the neoplastic compartment of tumors correlates with disease aggressiveness, often culminating in greater resistance to cytotoxic therapies or augmented metastatic potential. In this study, we found that subpopulations of dedifferentiated neoplastic breast epithelial cells express canonical leukocyte cell surface receptor proteins and have thus named this cellular program “immune mimicry.” Analysis of public human breast tumor single-cell RNA sequencing datasets and histopathologic breast tumor specimens, as well as functional experiments in vitro in breast cancer cell lines and in vivo in murine transgenic and cell line–derived mammary cancer models, showed that neoplastic cells engaged in immune mimicry. Immune-mimicked neoplastic cells harbored hallmarks of dedifferentiation and were enriched in treatment-resistant and high-grade breast tumors. In aggressive breast cancer cell lines, antiproliferative cytotoxic chemotherapies drove epithelial cells toward immune mimicry. The expression of the CD69 leukocyte activation protein by neoplastic cells conferred a proliferative advantage that facilitated early tumor growth. Together, these findings suggest that neoplastic breast epithelial cells upregulating leukocyte surface receptors potentiate malignancy and that neoplastic immune mimicry has potential clinical utility for patient prognosis and stratification. Significance: A subset of neoplastic breast epithelial cells express surface receptors canonically attributed to leukocytes and are associated with therapy resistance and aggressive tumor behavior.

2 February 2026
Verified
Other
Open access
EBEric B. Berens
Eric B. Berens
SKSokchea Khou
Sokchea Khou
EHElaine T. Huang
Elaine T. Huang
AHAmber Hoffman
Amber Hoffman
BJBriana Johnson
Briana Johnson
LCLisa M. Coussens
Lisa M. Coussens

2 February 2026
Verified
Other
Open access
EBEric B. Berens
Eric B. Berens
SKSokchea Khou
Sokchea Khou
EHElaine T. Huang
Elaine T. Huang
AHAmber Hoffman
Amber Hoffman
BJBriana Johnson
Briana Johnson
LCLisa M. Coussens
Lisa M. Coussens
CD45 depletion and expression time-course after doxorubicin in MDA-MB-231 cells

2 February 2026
Verified
Other
Open access
EBEric B. Berens
Eric B. Berens
SKSokchea Khou
Sokchea Khou
EHElaine T. Huang
Elaine T. Huang
AHAmber Hoffman
Amber Hoffman
BJBriana Johnson
Briana Johnson
LCLisa M. Coussens
Lisa M. Coussens
Paclitaxel treatment elicits immune mimicry in aggressive cell lines

2 February 2026
Verified
Other
Open access
EBEric B. Berens
Eric B. Berens
SKSokchea Khou
Sokchea Khou
EHElaine T. Huang
Elaine T. Huang
AHAmber Hoffman
Amber Hoffman
BJBriana Johnson
Briana Johnson
LCLisa M. Coussens
Lisa M. Coussens
Multiplexed immunohistochemistry examples of prospective CD45 and/or CD68 staining in neoplastic human breast epithelium